what stocks to buy now

Donald Trump cant point to much in the way of legislative victories over his first six months in office, but he might have something to crow about when it comes to a weaker U.S. dollar.

Much of the world has been waging a cold currency war since the autumn of 2016, and so far the winner is Donald Trump, wrote Joachim Fels, global economic adviser for asset manager Pimco, in a Wednesday blog post.

what stocks to buy now: Aaron's, Inc.(AAN)

Advisors’ Opinion:

  • [By Peter Graham]

    Just this morning, small cap consumer electronics retailer Aaron’s, Inc (NYSE: AAN) reported first quarter earnings that have beat expectations. First quarter revenues were$844.6 million compared with $854.4 million for the first quarter of 2016 whilenet earnings increased to $53.3 million compared with $49.7 million in the prior year period. The CEO commented:

  • [By Peter Graham]

    A long term performance chart shows shares of Best Buy Co now outperforming potential peersactive in electronics retailing such asmid capAaron’s, Inc (NYSE: AAN)and small cap CONN’S, Inc (NASDAQ: CONN):

  • [By Peter Graham]

    The Q4 2016 earnings report for small cap consumer electronics retailer Aaron’s, Inc (NYSE: AAN) is scheduled for before the market opens onFriday (February 17). Last time around, shares spiked in the high single digits after better-than-expected third quarterearnings.

  • [By Peter Graham]

    Small cap consumer electronics retailer Aaron’s, Inc (NYSE: AAN) reportedQ2 2017 earnings before the market opened on Friday. Revenues were $815.6 million versus $789.4 million. Progressive Leasing’s revenue in the second quarter of 2017 increased 25.1% to $373.5 million, revenue for DAMI was $8.5 million versus$5.3 million and overall revenues for the Aaron’s Business decreased 10.7% to $433.6 million. Same store revenues decreased 8.1% during the second quarter of 2017 and customer count on a same store basis was down 4.8%. Company-operated Aaron’s stores had 932,000 customersas ofJune 30, 2017, a 7.2% decrease from the second quarter of 2016. Net earnings were $36.3 million versus $38.5 million. The CEO commented:

  • [By Lisa Levin]

    Friday afternoon, the non-cyclical consumer goods & services sector proved to be a source of strength for the market. Leading the sector was strength from Align Technology, Inc. (NASDAQ: ALGN) and Aaron's, Inc. (NYSE: AAN).

  • [By Peter Graham]

    A long term performance chart shows shares of Best Buy Co outperforming potential peersactive in electronics retailing such asmid capAaron’s, Inc (NYSE: AAN)and small cap CONN’S, Inc (NASDAQ: CONN):

what stocks to buy now: Hanwha Q CELLS Co., Ltd. (HQCL)

Advisors’ Opinion:

  • [By Ashley Moore]

    We’ve compiled a list of the most heavily shorted stocks to show you which stocks have the most negative sentiment on the market…

    Company Name (Ticker)Short FloatShare PriceHanwha Q Cells Co. Ltd. (Nasdaq ADR: HQCL)98.52%$ 8.88Renren Inc. (NYSE: RENN)91.59%$ 8.53Weight Watchers International Inc. (NYSE: WTW)67.92%$12.57INSYS Therapeutics Inc. (Nasdaq: INSY)66.71%$10.74Twilio Inc. (NYSE: TWLO)66.34%$33.17Nutanix Inc. (Nasdaq: NTNX)65.65%$31.96Fitbit Inc. (NYSE: FIT)55.15%$ 6.06Weibo Corp. (Nasdaq ADR: WB)53.83%$55.26RPC Inc. (NYSE: RES)53.62%$21.19Straight Path Communications Inc. (NYSEMKT: STRP)49.27%$34.79Momo Inc. (Nasdaq ADR: MOMO)48.63%$26.80Seritage Growth Properties (NYSE: SRG)46.91%$44.87Lannett Company Inc. (NYSE: LCI)45.46%$23.00Gogo Inc. (Nasdaq: GOGO)43.98%$ 9.10Altisource Portfolio Solutions SA (Nasdaq: ASPS)42.78%$22.73Cheetah Mobile Inc. (NYSE ADR: CMCM)40.86%$10.00

    Some investors think the only way to profit from the stock market is to buy stocks and wait for the price to rise. However, these investors are missing out on the massive profit opportunity that comes from shorting stocks.

what stocks to buy now: Lifeway Foods, Inc.(LWAY)

Advisors’ Opinion:

  • [By Jim Robertson]

    Last Friday, our Under the Radar Moversnewsletter suggested shorting small capdairy health food product stock Lifeway Foods, Inc (NASDAQ: LWAY):

  • [By Peter Graham]

    A long term performance chart for Dean Foods Co shows a positive but not spectacular long term return as small cap Lifeway Foods, Inc (NASDAQ: LWAY) has been more volatile and non-dairy desert stock Tofutti Brands Inc (NYSEMKT: TOF) has given a moderately positive performance:

what stocks to buy now: Brady Corporation(BRC)

Advisors’ Opinion:

  • [By Shauna O’Brien]

    Robert Baird announced on Friday that it has cut its rating on Brady Corp (BRC).

    The firm has downgraded BRC from “Outperform” to “Neutral,” and has given the company a $33 price target. This price target suggests a 8% upside from the stock’s current price of $30.52.

    Analysts see the company’s WPS segment growing faster than expected.

    Brady shares were mostly flat during pre-market trading Friday. The stock is down 9% YTD.

  • [By Michael Flannelly]

    Before the opening bell on Thursday, identification solutions provider Brady Corp (BRC) posted a loss in the fourth quarter, despite a rise in revenues, as it was negatively impacted by a number of charges. However, excluding these charges, the company was able to top Wall Street analysts’ earnings and sales estimates. Nonetheless, BRC shares are plummeting in Thursday’s trading.

    The Milwaukee, Wisconsin-based company posted a loss from continuing operations of $176.2 million, or $3.41 per share, in the fourth quarter, versus last year’s fourth quarter earnings from continuing operations of $20.9 million, or 40 cents per share. Furthermore, Brady posted a net loss of $177.2 million, or $3.43 per share, compared to net earnings of $11.6 million, or 22 cents per share, in the same period a year ago.

    The fourth quarter loss includes non-cash impairment charges of $204.4 million, $15.6 million in restructuring charges, and $4 million in acquisition-related charges. Excluding these charges, Brady Corp said earnings would have been 53 cents per share in the quarter. According to analysts polled by Thomson Reuters, the company was expected to earn an adjusted 51 cents per share in the fourth quarter.

    The company’s fourth quarter sales came in at $309.1 million, up 15% from $269.1 million in sales posted last year. On average, analysts were expecting the company to see $307.13 million in revenues for the quarter.

    Looking ahead, Brady Corp. sees fiscal 2014 earnings coming in between $1.80 and $2.00 per share, below the analysts’ view of $2.30 per share.

    Brady Corp shares were down $1.71, or 5.25%, during early morning trading on Thursday. The stock is up 7.93% year-to-date.

  • [By Mike Deane]

    For the 28th year in a row, Brady Corp (BRC) has increased its dividend payout to investors.

    The Milwaukee, WI-based company increased its quarterly dividend to 19.5 cents from 19 cents, an increase of 2.6%. The annual dividend now stands at 78 cents. The quarterly dividend will be paid on October 31st, 2013 to all shareholders of record on October 10, 2013.

    BRC shares were down 40 cents, or 1.23%, by market close on Wednesday. YTD, the company’s stock is down over 4%.

what stocks to buy now: MannKind Corporation(MNKD)

Advisors’ Opinion:

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday's regular session.

  • [By Ben Levisohn]

    Hopes were high for MannKind (MNKD) when its inhaled insulin Afrezza was approved by the FDA more than two years ago. At the time, Barron’s warned that it was time to dump MannKind’s shares, something that now seems prescient, as its shares have since tumbled 95%. No wonder, as the news since then has been far from good. MannKind found a partner in Sanofi (SNY), only to get dumped in early 2016, and has since been forced to sell property to raise cash. And now MannKind could be on the verge of being delisted from the Nasdaq due to its sub $1 stock price. What now? Piper Jaffray’sJoshua Schimmer and team see a reverse stock split in MannKind’s future:

    [MannKind] has been focused on relaunch of Afrezza (inhaled insulin) for diabetes since Sanofi terminated its partnership for that program last year. Progress has been slow as the company first deployed a contract sales force but is now switching to an internal one. Hiring is nearly complete and reps will be out in the field soon. The company has also made strides in expanding reimbursement coverage for Afrezza. MannKind is also in the process of launching a new Titration Pack for Afrezza that allows for greater dosing flexibility in an attempt to simplify prescribing patterns of the drug. However with all these efforts, scrips have not yet shown signs of life in a very crowded diabetes market where MannKind is likely to struggle to claim share of voice relative to large pharma competitors. MannKind held a special meeting of stockholders in February 2017 in order to gain authority for a reverse stock split, if necessary to avoid de-listing by NASDAQ. MannKind recently indicated its cash position to be at ~$120M (and added $17M from the sale of its Valencia facility in February), which does provide some room to grow Afrezza sales before having to seek out yet another dilutive raise. However, its unclear if any of the new commercial efforts will help to rescue Afrezza sales. Ou

  • [By Lisa Levin]

    MannKind Corporation (NASDAQ: MNKD) shares were also up, gaining 24 percent to $6.59. H.C. Wainwright initiated coverage on MannKind with a Buy rating and a $7.00 price target.

  • [By Chris Lange]

    MannKind Corp. (NASDAQ: MNKD) saw the number of its shares short increase slightly to 98.71 million. The previous reading was 97.07 million. The stock closed most recently at $0.55, in a 52-week range of $0.41 to $2.24. Note that MannKind is one of the most shorted Nasdaq stocks.

  • [By Lisa Levin]

    In trading on Tuesday, healthcare shares fell 0.48 percent. Meanwhile, top losers in the sector included MannKind Corporation (NASDAQ: MNKD), down 10 percent, and BioDelivery Sciences International, Inc. (NASDAQ: BDSI) down 10 percent.

  • [By James E. Brumley]

    When most investors think of diabetes stocks, names like Novo Nordisk A/S (ADR) (NYSE:NVO) and MannKind Corporation (NASDAQ:MNKD) come to mind. And well they should. Novo Nordisk is the biggest insulin company in the world, and while MannKind is relatively small, it’s a name that turns heads simply because it came up with an inhalable insulin that – after a slow start – is getting a little traction.

    In both cases though, the paradigm is the same one that was first used decades ago. That is, if a person isn’t making their own insulin, then it must be introduced externally. What if instead a diabetic’s glucose levels could be controlled by turning on the cells in their body responsible for processing that sugar? That’s the approach Cell MedX Corp (OTCMKTS:CMXC) is taking, using a relatively new but very compelling science.

    While chemical-based manufactured pharmaceuticals were largely the core of healthcare for well over the past century, it’s become clear that our bodies – right down to our cells – are also electrical in nature. Not only do they produce it, they need it to function properly. The FDA has even recently approved a therapeutic device that delivers mild electrical currents to and through an individual’s body as a means of treating pain. This “electromedicine” has also shown a certain degree of efficacy as a treatment for several illnesses, including cancer. Specifically, electrical currents have been demonstrated to force pleomorphic cancer microbes into hibernation, essentially making a cancerous cell a normal, healthy cell again. So, using an electrical current as a means of therapy for diabetics isn’t far-fetched at all. Indeed, it’s quite brilliant.

    As for how Cell MedX is using the idea, it’s actually quite simple. The device is called an eBalance. At first glance it just looks like another ordinary tablet computer. A closer inspection of the e-Balance device, however, makes it clear that it’s not just another tablet. It’

what stocks to buy now: Amphenol Corporation(APH)

Advisors’ Opinion:

  • [By Lee Jackson]

    This is the top pick in the sector and has remained a favorite at RBC for some time.Amphenol Corp. (NYSE: APH) is one of the worlds largest designers, manufacturers and marketers of electrical, electronic and fiber optic connectors, interconnect systems, antennas, sensors and sensor-based products and coaxial and high-speed specialty cable.

  • [By Darren Williams] Although the entire cannabis space has quietly taken a hit of their own medicine in recent weeks and gone to sleep, don’t think for one second the entire space isn’t going to light up again soon. That’s just what they do, right? However, knowing who the pretenders are and knowing who the contenders are is really the challenge when it’s comes right down to it.
    First, anyone who claims to be a grower or a seller of cannabis can’t for one second ever make it as a public company right now, or can even legally consider being a public company for that matter, so you can scratch any of those right off your list. At least here in the U.S. anyway, because Canada is already well ahead of the curve having legalized it for medicinal purposes already.
    More importantly, full legalization of marijuana in Canada appears to be on track for July 2018, which will make Canada just the second nation in the world after Uruguay to completely legalize the cultivation, sale and possession of the drug for medical and recreational purposes.
    Regardless, the best time to buy any stocks in a hot growth sector is when either everyone has forgotten about them, or when the overall market landscape has turned bearish, which has yet to happen. However, the former seems to be the case for the cannabis space, despite some very favorable state legislation last Fall.
    For now, as long as you have a license issued by Health Canada, you’re good to go, so there are some stocks trading in Canada already who are well on their way to making some green for investors. Canopy Growth Corporation (TSE: WEED), formerly Tweed Marijuana Inc., is a medical marijuana company based in Smiths Falls, Ontario. Aurora Cannabis Inc. (CVE: ACB), which is engaged in the production and sale of medical cannabis. There’s also Aphria Pharmaceutical Company (TSE: APH), which also is engaged in producing and selling medical marijuana through retail sales and wholesale channels.
    There are many more, but those are just a

Leave a Reply

Your email address will not be published. Required fields are marked *